Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
April 2004
Article
Abstract Adoptive transfer of antigen-specific T cells has recently shown therapeutic successes in the treatment of viral infections and tumors. T cells specific for the antigen of interest can be generated in vitro, and adoptively transferred back to provide patients with large numbers of immune-competent T cells. Adoptive T cell therapy, however, is a patient-tailored treatment that unfortunately is not universally applicable to treat viral infections and tumors. We and others have demonstrated that the transfer of genes encoding antigen-specific receptors into T cells (i.e., genetic retargeting) represents an attractive alternative to induce antigen-specific immunity. Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes
- cytology
- metabolism
- Animals
- In Vitro
- Humans
- Mice
- Treatment Outcome
- cancer
- genetics
- Clinical Trials
- immunology
- Flow Cytometry
- therapy
- Review
- Lymphocyte Count
- Lymphocytes
- Genes
- Adoptive Transfer
- Liver
- T lymphocytes
- Antibodies,Monoclonal
- T Cell
- T-Lymphocytes,Cytotoxic
- therapeutic use
- Carcinoma,Renal Cell
- RECEPTOR
- Transduction,Genetic
- immunogene therapy
- methods
- G250
- Research
- IM
- Immunity
- Medical Oncology
- RCC
- Renal cell cancer
- Antigens,Neoplasm
- CHAIN
- Cytotoxicity Tests,Immunologic
- Immunoglobulin Fragments
- Immunotherapy,Adoptive
- Infection
- Interferon Type II
- Receptors,Antigen,T-Cell
- TRIAL
- Transplantation,Autologous
- Tumor
- Xenograft Model Antitumor Assays
- adverse effects
- physiopathology
